This may also potentially explain why some PD-L1-negative patients still benefit from therapy or vice versa, as the immune composition of their tumor microenvironment may have fluctuated since the time of biopsy and the location of the tissue acquisition. The gene discussed is CD274; the disease is neoplasm.